An investigation of therapeutic efficacy when switching from intensive insulin therapy to long-acting insulin plus either dulaglutide or empagliflozin in type 2 diabetes patients
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000036788
- Lead Sponsor
- Chigasaki Municipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with serious hepatic dysfunction 2. Patients with serious renal dysfunction 3. Patients taking steroids 4. Patients with cancer 5. Patients with severe infection or serious injury 6. Patients who are or could be pregnant 7. Patients with an allergy to the drug to be used or for whom it is contraindicated 8. Any other patients considered by the investigator or a subinvestigator to be unsuitable to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in HbA1c from before switching treatment to 24 weeks after switching
- Secondary Outcome Measures
Name Time Method fasting blood glucose 2-h postprandial glucose GA insulin secretion capacity pancreatic glucagon flash glucose monitoring Self-monitoring of blood glucose results renal function urinary albumin L-FABP Body weight BMI body composition waist circumference blood pressure heart rate lipids UA hepatic function total protein albumin electrolytes insulin dose Evaluation of satisfaction with treatment appetite Adverse events